2014 ASX Announcements

26 August 2014

Preliminary Final Report Year Ended 30 June 2014

30 July 2014

Update to Interim Phase III Results for PI-88

29 July 2014

Interim Phase III Results for PI-88

 

21 July 2014

European Patent Office Intention to Grant Sulfated Oligosaccharide Derivatives Patent


9 July 2014

Medigen Schedules PI-88 Interim Patient Analysis July 2014.pdf

 

28 May 2014

Change of Head Office Address

19 May 2014

Change of Director's Interest Notice 


15 May 2014

PG545 Phase 1 Clinical Trial Successfully Completes First Patient Cohort

 

14 May 2014

Changes to Management and Corporate Office Address

 

9 May 2014

Medigen Expects PI-88 Interim Patient Data in May 2014

 

29 April 2014

Medigen Biotechnology Engages Pharmasynth to Manufacture PI-88 Registration Batches

 

28 April 2014

Notice of Allowance of US patent for PG545 & related compounds

 

9 April 2014

PG545 Data Presented at AACR Conference


02 April 2014

Issue of Unlisted Options under Employee Share Option Plan 2 April 2014

 

13 March 2014

Appendix 3Y Change of Director's Interest Notice

 

28 February 2014

Appendix 4D - Interim Financial Report

 

13 February 2014

PG545 Data Presented at Lorne Cancer Conference

 

31 January 2014

Receipt of R&D Tax Incentive Refund

 

2013 ASX Announcements

30 December 2013

PATRON Trial Completes Patient Recruitment

 

20 December 2013

Lodgement of Change in Director's Interest Notice

 

17 December 2013

R&D Tax Incentive 17 Dec 2013

 

17 December 2013

2013 Form 20-F A Filed with US SEC

 

6 December 2013

Change of Director's Interest Notice

 

3 December 2013

Beta Therapeutics Assignment Agreement

 

2 December 2013

Initial Director's Interest Notice Appendix 3X

 

29 November 2013

Final Director's Interest Notice Appendix 3Z


29 November 2013

2013 Annual General Meeting Address

 

29 November 2013

Appointment of Director and Chair

 

28 November 2013

Results of 2013 Annual General Meeting

 

26 November 2013

Change to Board of Directors

 

1st November 2013

2013 Form 20-F Filed with the US SEC.pdf


30th October 2013

PG545 Phase 1 Cancer Trial Update


25th October 2013

2013 Annual General Meeting Documentation


22nd October 2013

Change to Acting Managing Director's Terms of Employment


8th October 2013

Issue of Unlisted Options under Employee Share Option Plan


28th August 2013

Preliminary Final Report Year Ended 30 June 2013


12th July 2013

PI-88 Phase III Update


12th July 2013

Appendix 3X Initial Director's Interest Notice


12th July 2013

Appendix 3Z Final Director's Interest Notice


12th July 2013

Board & Senior Management Changes

 

9th July 2013

PG545 Published in Molecular Cancer Therapeutics


5th June 2013

Form 605 - Notice of Ceasing to be a Substantial Holder


30th May 2013

Form 605 - Notice of Ceasing to be a Substantial Holder


29th May 2013

Form 604 - Notice of Change of Interest of Substantial Holder

 

29th May 2013

Form 603 - Notice of Initial Substantial Holder


29th May 2013

Notice Under Section 708A(5)(e)


27th May 2013

Completion of Share Placement


27th May 2013

Change in Substantial Holding

 

22nd May 2013

Non-Renounceable Rights Issue Share Allotment


22nd May 2013

Notice Under Section 708A(5)(e)

 

22nd May 2013

Appendix 3Y Change of Director's Interest Notice


22nd May 2013

Appendix 3Y Change of Director's Interest Notice 22May13

 

21st May 2013

Notification of Subscriptions


1st May 2013

Dispatch of Non-Renounceable Rights Issue Offer Document

 

18th April 2013

Notice to Eligible Shareholders 18 Apr 2013


18th April 2013

Notice to Ineligible Shareholders


17th April 2013

Rights Issue - Notice Under Section 708AA(2)(f)


17th April 2013

Non-Renounceable Rights Issue Offer - Letter to Option Holders


17th April 2013

Offer Document


16th April 2013

Non Renounceable Pro Rata Rights Issue


16th April 2013

Appendix 3B

 

26th March 2013

Appendix 3Y


12th March 2013

Change of Director's Interest Notice

 

1st March 2013

Progen Pharmaceuticals signs License with Medigen Biotech Corp

 

31st January 2013

Receipt of R&D Tax Incentive Refund

 

31st January 2013

Qld Storm - Operations Unaffected

 

11th January 2013

R&D Tax Incentive Refund

2012 ASX Announcements

 

31st December 2012

Appendix 4D Interim Financial Report


28th December 2012

Progen Pharmaceuticals Ltd signs Binding License Term Sheet

 

6th December 2012

Appendix 3Yf

 

4th December 2012

2012 Form 20-F Filed with the US SEC

 

25th September 2012

Appendix 3Y 25 Sept 12